Semaglutide
GLP-1 agonist for weight loss and type 2 diabetes treatment. The active ingredient in Ozempic and Wegovy with proven clinical efficacy.
What is Semaglutide?
Semaglutide is a long-acting GLP-1 receptor agonist. Known as the active ingredient in Ozempic (for diabetes) and Wegovy (for obesity). It slows gastric emptying, reduces appetite, and improves insulin sensitivity.
Injection Protocol
Starting dose: 250 mcg (0.25 mg) subcutaneously once weekly for 4 weeks.
- Weeks 1–4: 250 mcg
- Weeks 5–8: 500 mcg
- Weeks 9–12: 1000 mcg
- Weeks 13–16: 1700 mcg (maintenance)
- Week 17+: up to 2400 mcg (maximum)
Vial Reconstitution
Reconstituting a 2 mg vial with 2 ml bacteriostatic water gives 1 mg/ml:
- 250 mcg = 0.25 ml = 25 units (U-100)
- 500 mcg = 0.5 ml = 50 units (U-100)
- 1000 mcg = 1 ml = 100 units (U-100)
Storage
Unreconstituted vial: refrigerate. After reconstitution: refrigerate up to 28 days. Do not leave at room temperature for more than 3 hours.
Important Warnings
- Nausea and vomiting are common, especially when increasing dose.
- Risk of "Ozempic face" (facial fat loss) with rapid weight loss — track protein intake.
- Contraindicated with personal or family history of medullary thyroid carcinoma.
Rapid weight loss burns muscle. Avoid Ozempic face by tracking your protein intake.
Check Protein Norm